Grail Inc Stock News

Grail stock fell late Wednesday after the next-generation sequencing company reported light third-quarter sales.

FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000 Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million SUNNYVALE, Calif., Nov. 4, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company ...

For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.

An advisory panel to the US Food and Drug Administration handed Grail's Galleri blood test a milestone win last week, saying the early cancer detection test's potential benefits outweigh its risks and bringing it a step closer to approval.

Grail stock surged Thursday after a panel of advisors to the FDA backed the company's cancer-detecting blood test.

There are many unrecognized trade-offs to home ownership that can make renting a better economic choice.

The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.